These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 23122594)
1. Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin. Tan H; Yang S; Liu C; Cao J; Mu G; Wang F Biomed Pharmacother; 2012 Dec; 66(8):648-54. PubMed ID: 23122594 [TBL] [Abstract][Full Text] [Related]
2. Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin. Tan H; Yang S; Feng Y; Liu C; Cao J; Mu G; Wang F J Biochem; 2008 Aug; 144(2):207-13. PubMed ID: 18463113 [TBL] [Abstract][Full Text] [Related]
4. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug. Tan H; Mu G; Zhu W; Liu J; Wang F Biol Pharm Bull; 2011; 34(4):545-50. PubMed ID: 21467643 [TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization. Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141 [TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization and anti-angiogenesis activity of endostatin covalently modified by polysulfated heparin. Ning TH; Chao CJ; Ying MG; Min X; Shan WF Pharmazie; 2012 Jul; 67(7):622-7. PubMed ID: 22888520 [TBL] [Abstract][Full Text] [Related]
7. Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin. Sun F; Shaikh AS; Wang J; Gao H; Yang Z; Wang Z; Li Y; Wang F; Tan H Curr Pharm Biotechnol; 2018; 19(12):996-1004. PubMed ID: 30761959 [TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Schuch G; Oliveira-Ferrer L; Loges S; Laack E; Bokemeyer C; Hossfeld DK; Fiedler W; Ergun S Leukemia; 2005 Aug; 19(8):1312-7. PubMed ID: 15931265 [TBL] [Abstract][Full Text] [Related]
9. Augmented anti-angiogenesis activity of polysulfated heparin-endostatin and polyethylene glycol-endostatin in alkali burn-induced corneal ulcers in rabbits. Li ZN; Yuan ZF; Mu GY; Hu M; Cao LJ; Zhang YL; Ge MX Exp Ther Med; 2015 Sep; 10(3):889-894. PubMed ID: 26622410 [TBL] [Abstract][Full Text] [Related]
10. Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa. Zhu B; Xu HM; Zhao L; Huang X; Zhang F J Biochem; 2010 Sep; 148(3):341-7. PubMed ID: 20587645 [TBL] [Abstract][Full Text] [Related]
11. [Inhibition of corneal neovascularization by liposomes mediated plasmid encoding human endostatin]. Niu XG; Wang W; Shi WY; Xie LX Zhonghua Yan Ke Za Zhi; 2005 Mar; 41(3):260-4. PubMed ID: 15840371 [TBL] [Abstract][Full Text] [Related]
12. Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate. Lee DY; Kim SK; Kim YS; Son DH; Nam JH; Kim IS; Park RW; Kim SY; Byun Y J Control Release; 2007 Apr; 118(3):310-7. PubMed ID: 17291620 [TBL] [Abstract][Full Text] [Related]
13. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021 [TBL] [Abstract][Full Text] [Related]
14. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy. Alam F; Al-Hilal TA; Chung SW; Park J; Mahmud F; Seo D; Kim HS; Lee DS; Byun Y J Control Release; 2015 Jan; 197():180-9. PubMed ID: 25445701 [TBL] [Abstract][Full Text] [Related]
15. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent. Cho H; Kim WJ; Lee YM; Kim YM; Kwon YG; Park YS; Choi EY; Kim KW Oncol Rep; 2004 Jan; 11(1):191-5. PubMed ID: 14654925 [TBL] [Abstract][Full Text] [Related]
16. Endostatin specifically targets both tumor blood vessels and lymphatic vessels. Zhuo W; Chen Y; Song X; Luo Y Front Med; 2011 Dec; 5(4):336-40. PubMed ID: 22198745 [TBL] [Abstract][Full Text] [Related]
17. Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice. Schaffhauser B; Veikkola T; Strittmatter K; Antoniadis H; Alitalo K; Christofori G J Leukoc Biol; 2006 Oct; 80(4):669-76. PubMed ID: 16793908 [TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effect of local injectable hydrogel-loaded endostatin alone and in combination with radiotherapy for lung cancer. Wang N; Gao Q; Tang J; Jiang Y; Yang L; Shi X; Chen Y; Zhang Y; Fu S; Lin S Drug Deliv; 2021 Dec; 28(1):183-194. PubMed ID: 33427520 [TBL] [Abstract][Full Text] [Related]
19. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives. Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408 [TBL] [Abstract][Full Text] [Related]
20. The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin. Lim J; Duong T; Lee G; Seong BL; El-Rifai W; Ruley HE; Jo D Biomaterials; 2013 Aug; 34(26):6261-71. PubMed ID: 23714245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]